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Abstract
Background: Every year, 90,000 people may die from melioidosis. Vaccine candidates have not proceeded past
animal studies, partly due to uncertainty around the potential market size. This study aims to estimate the potential
impact, cost-effectiveness and market size for melioidosis vaccines.
Methods: Age-structured decision tree models with country-specific inputs were used to estimate net costs and
health benefits of vaccination, with health measured in quality-adjusted life years (QALYs). Four target groups of
people living in endemic regions were considered: (i) people aged over 45 years with chronic renal disease, (ii)
people aged over 45 years with diabetes, (iii) people aged over 45 years with diabetes and/or chronic renal disease,
(iv) everyone aged over 45 years. Melioidosis risk was estimated using Bayesian evidence synthesis of 12
observational studies. In the base case, vaccines were assumed to have 80% efficacy, to have 5-year mean
protective duration and to cost USD10.20–338.20 per vaccine.
Results: Vaccination could be cost-effective (with incremental cost-effectiveness ratio below GDP per capita) in
61/83 countries/territories with local melioidosis transmission. In these 61 countries/territories, vaccination could
avert 68,000 lost QALYs, 8300 cases and 4400 deaths per vaccinated age cohort, at an incremental cost of USD59.6
million. Strategy (ii) was optimal in most regions. The vaccine market may be worth USD268 million per year at its
threshold cost-effective price in each country/territory.
Conclusions: There is a viable melioidosis vaccine market, with cost-effective vaccine strategies in most countries/
territories with local transmission.
Keywords: Melioidosis, Infections, Vaccine, Cost-effectiveness, Economic evaluation
Background
Burkholderia pseudomallei is a highly pathogenic gram-
negative bacillus that is the causal agent of melioidosis [1].
The bacteria are present mainly in soil and water, and
people are infected through inoculation, ingestion and in-
halation [2]. A recent study estimated that melioidosis is
endemic in 83 countries/territories (hereafter “geograph-
ies”), mainly in South-East Asia and sub-Saharan Africa,
and that it causes 164,938 cases and 88,979 deaths annu-
ally [3]. Major risk factors for infection include diabetes,
chronic renal and lung disease, immunosuppression and
excess alcohol consumption [4, 5]. The indigenous popu-
lation in Australia is also at higher risk of melioidosis. B.
pseudomallei is resistant to many antibiotics, and ex-
tended courses of treatment, often using multiple drugs,
are typically required [1, 6]. In addition, many cases of
melioidosis are advanced when diagnosed and treated, so
mortality is high [1].
Consequently, a vaccine could be valuable for the pre-
vention of disease in many parts of the world. Several
vaccine candidates have shown promising results in ani-
mals but to date no human studies have been conducted
[7, 8]. A recent study showed that a melioidosis vaccine
could be cost-effective in north-eastern Thailand if it
protects for at least 3 years and can reduce both inci-
dence and mortality of melioidosis by at least 80%; the
threshold cost-effective price was $1 for vaccinating
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everyone aged 35 years and $8 for vaccinating diabetics
aged over 35 years ([7] and Yoel Lubell, personal com-
munication). However, no economic analyses have been
conducted outside this location.
Establishing a cost-effective strategy for the use of a
melioidosis vaccine in different countries, and hence the
size of the potential global market for the vaccine, is key
to unlocking investment into further vaccine develop-
ment. It can also help guide local decision makers about
optimal vaccine use if a vaccine becomes available.
Hence, our main objective is to assess the potential
impact and cost-effectiveness of different strategies for
using a melioidosis vaccine, at a global level.
Methods
Overview
We estimated the impact and cost-effectiveness of meli-
oidosis vaccination in 83 geographies where melioidosis
is believed to be endemic [3]. In each location, we esti-
mated the burden of melioidosis in three subpopulations
at high risk of disease: people aged over 45 years old,
diabetics and chronic renal disease patients. To do this,
we used a Bayesian model to synthesise information
extracted from 12 observational studies reported in a
recent systematic review to estimate the relative risk of
melioidosis in these groups [3]. These estimated relative
risks were applied to our estimates of melioidosis inci-
dence in every geography to quantify the incidence in
people with one or more of these risk factors.
Incidence estimates were then combined with geography-
specific epidemiological, demographic and clinical pa-
rameters to examine the impact of different vaccination
strategies. Four target populations for vaccination were
examined: (i) people aged over 45 years with chronic
renal disease (Vac 1), (ii) people aged over 45 years with
diabetes (Vac 2), (iii) people aged over 45 years with
diabetes and/or chronic renal disease (Vac 3) and (iv)
people aged over 45 years (Vac 4). In each case, vaccin-
ation was assumed to be confined to areas identified as
having environmental conditions suitable for B. pseudo-
mallei in the global burden study [3].
Using these impact estimates, a cost-effectiveness ana-
lysis was conducted in each geography by estimating the
incremental cost (in USD) per quality-adjusted life year
(QALY) gained for each strategy. This analysis consid-
ered the cost and QALY loss due to hospitalised and
fatal melioidosis, as well as the cost of vaccination.
Model structure
The disease model assumes that melioidosis is transmit-
ted through contact with the environment (soil, water),
since there is no evidence of person-to-person transmis-
sion [9]. A geography-specific age-structured static deci-
sion tree model with lifetime horizon was developed
(Fig. 1) containing four melioidosis endpoints based on
clinical acquisition and presentation: (i) acute disease with
complications, (ii) acute disease without complications,
(iii) chronic disease with systemic illness and (iv) chronic
disease without systemic illness [10]. The geography-
specific overall mortality due to melioidosis was assumed
to be the same as predicted in the global burden study [3].
Patients who survive a melioidosis episode were as-
sumed to return to full health with the same life expect-
ancy as the general population but may experience
Fig. 1 Decision tree showing that vaccination is offered at age 46 and the cohort is followed up until age 100
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another episode later in life. We assumed that life ex-
pectancy was the same for anyone living in a particular
country, due both to lack of data about life expectancy
in different risk groups as well as to avoid ethical diffi-
culties around discriminating against risk groups with
lower life expectancy in economic evaluations [11].
Definitions of the different clinical presentations of
melioidosis were adopted from Ketheesan et al. [12]
(Additional file 1: Table S1). The total number of cases
and deaths per year matched numbers reported in the
recent global burden study [3]. A geography-specific life-
time cohort model stratified by age groups was developed.
The population aged 46 that received vaccination was
treated as a single cohort and followed up until death.
Data and parameter inputs
Population at risk: general and environment suitable area
We assumed that melioidosis cases were confined to
people living in a geographical region environmentally
suitable for melioidosis transmission. Environmental
suitability was defined in the same way as in Limmathur-
otsakul et al., i.e. any location in the fifth percentile of
positive occurrence records (or at least 0.1567 on the
0–1 predicted environmental suitability scale) in that
paper [3]. Areas matching the definition (by 5 km× 5 km
quadrants) were matched to the population density map
derived from Global Rural-Urban Mapping Project
(GRUMP) 2010 adjusted for population per geography
in the 2015 United Nations World Population Pros-
pects to estimate geography-specific population at risk
for melioidosis [3, 13].
Relative risk of melioidosis for different risk factors
We estimated the relative risk of contracting melioidosis
for three risk factors: age over 45 years, diabetes and
chronic renal disease. Studies reporting the incidence of
melioidosis identified in a recent systematic review were
included in this analysis [3]. Of the 20 observational
studies (Additional file 1: Text S1) reporting the number
of cases with different potential risk factors, only 11 re-
ported the proportion of cases related to either diabetes,
chronic renal disease, or age group [4, 5, 14–22]. All of
these studies reported the number of diabetic cases
while ten studies revealed the number of cases with
chronic renal disease. Six studies reported the number
of cases aged over either 40, 45, 50 or 55 years.
We synthesised information in each study to determine
global relative risks, assuming that they do not differ across
studies and geographies. A Poisson log-likelihood function
was used to fit estimates of relative risks to observed
counts of melioidosis cases in each of eight risk subgroups
(i.e. people with no risk, diabetes, chronic renal disease,
age over 45 years or any combination of these) within a
Bayesian framework. We assumed that the prevalence of
risk factors in each study was the same as that in the gen-
eral population in the same geography. Markov Chain
Monte Carlo (MCMC) was then used to estimate the mar-
ginal probabilities for the relative risk of melioidosis in
different groups. The risk of melioidosis in people with a
combination of risk factors was assumed to be the product
of the marginal risks. The estimated relative risks were
then compared with the population with no risk factors
defined as the population aged under 45 without either
diabetes or chronic renal disease. Although there are
slight differences in the age threshold for being high
risk across the studies (ranging from 40 to 55), we as-
sumed that the threshold across all studies was 45 years.
(Additional file 1: Figure S1 (a-c), Table S2 and Text S2).
Risk of melioidosis and risk of death
The incidence of melioidosis in environmentally suitable
areas in each geography for people with either single or
combined risk factors of being over 45 years, diabetic
and/or having chronic renal disease was estimated from
the predicted relative risks. (Additional file 1: Table S3
for details). The risk of each of the four melioidosis end-
points (acute disease with and without complication;
chronic disease with and without systemic illness) was
estimated by expert elicitation due to paucity of data in
the literature (Additional file 1: Text S3 for the question-
naire used). These parameters were assumed to be the
same for every geography. The parameters to be esti-
mated were independently presented to four clinicians
with experience of melioidosis (authors D.A.B.D., D.L.,
B.J.C. and C.M.) to estimate the proportion and risk of
death for each of the melioidosis conditions, and the
fraction of intensive care admission among acute meli-
oidosis with complication patients. The median, mini-
mum and maximum values from the four respondents
were fitted with gamma distribution. Geography-specific
overall number of cases and deaths due to melioidosis
were obtained from the incidence and mortality pre-
dicted each year in the global burden study [3].
Demographic data
In most geographies, age-specific life expectancy was
estimated from World Health Organisation life tables,
2015 [23]. Three countries without life tables (Sierra
Leone, Guinea-Bissau and Gambia) were matched to life
tables in Uganda, Somalia and Liberia respectively based
on geographical and income similarity. Life tables for
Hong Kong were obtained from the city’s National Census
and Statistics Department [24]. The geography-specific
prevalence of diabetes and chronic renal disease were re-
spectively obtained from the International Diabetes Federa-
tion’s Diabetes Atlas, 2012 (available at geography-level)
and a systematic review (available at regional level) [25, 26],
Luangasanatip et al. BMC Medicine          (2019) 17:129 Page 3 of 11
Table 1 Parameters used in the analysis
Values References
Risk of melioidosis (baseline) See Additional file 1: Table S3(a)
Relative risk of melioidosis by risk factor
- Age > 45 years 2.01 (1.87, 2.15) Estimated from literature
- Diabetes 6.50 (6.10, 6.93) Estimated from literature
- Chronic renal disease 1.33 (1.20, 1.46) Estimated from literature
Probability of each condition given melioidosis infection
(3 levels; high-, middle- and low-income geographies)
High Middle Low
Probability of acute disease with complications 0.40 0.50 0.25 Expert opinion
Probability of acute disease without complications 0.48 0.40 0.55 Expert opinion
Probability of chronic disease with systemic illness 0.07 0.05 0.07 Expert opinion
Probability of chronic disease without systemic illness 0.06 0.05 0.12 Expert opinion
Risk of death (relative risk for each condition)
Baseline risk of death (chronic disease without systemic illness) Vary between geographies Estimated
Relative risk for acute disease with complications 16.42 Expert opinion
Relative risk for acute disease without complications 5.33 Expert opinion
Relative risk of chronic disease with systemic illness 5.17 Expert opinion
Probability of intensive care unit admission among acute cases with
complication
0.62 (0.48, 0.75) Expert opinion
Economic parameters
Resource use
Length of hospital stay (LOS) Median (95% CI) Indian hospital data
Intensive care unit (ICU) for acute disease with complication cases 3.20 (0.58, 10.04)
General hospitalisation
- Acute disease with complication 13.85 (1.66, 34.71)
- Acute disease without complication 14.77 (2.51, 34.35)
- Chronic disease with systemic illness 18.19 (4.20, 41.61)
- Chronic disease without systemic illness 15.36 (1.06, 41.81)
Treatment duration (days) [10]
- Parenteral regimens 12 (10, 14)
Meropenem or ceftazidime
- Oral regimens 112 (84, 140)
Trimethroprim/sulfamethoxazole or co-amoxiclav
Costs (USD, 2016)
Cost of vaccine (complete course) by country income level Low 10.2
Middle 43.5
High 338.2
[27]
Cost per bed day WHO-CHOICE [31]
Cost per ICU bed day
Ratio between ICU and general bed day by income level High 2.56
Middle 7.92
Low 13.28
See Additional file 1: Table S3(b)
Antibiotics (per day), children aged < 15 years High Middle Low
Meropenem 46.78 59.47 N/A [32, 33]
Ceftazidime 27.89 3.44 3.44
Trimethoprim/sulfamethoxazole 0.91 0.05 0.05
Co-amoxiclav 0.71 1.41 1.41
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assuming these figures are homogeneous across geograph-
ical regions and age groups, within the same geography.
Vaccination strategies and cost-effectiveness analysis
The costs of melioidosis treatment were estimated by
micro-costing assuming melioidosis cases were treated
with regimens in compliance with treatment guidelines
[10] (see Additional file 1: Text S4 for details). Because
licenced melioidosis vaccines are not currently available,
we assumed the total costs of vaccination to be
USD10.2, 43.5, and 338.2 in low-, middle- and high-
income countries, respectively. This was based on the
total cost of purchasing and delivering a 2-dose course
of human papillomavirus (HPV) vaccines in countries
from different income levels [27]. Health-related quality
of life due to melioidosis infections regardless of end-
point was assumed to be similar to bacteraemia [28].
Total QALY loss was then estimated by multiplying the
length of hospitalisation for the melioidosis endpoint
with the quality of life weight, adjusting for population
norms (i.e. the fact that the baseline population is not in
perfect health) [29]. Vaccine efficacy was assumed to be
80% (for an all-or-nothing vaccine), with protection
waning exponentially with a mean duration of 5 years in
the base case [7].
For each vaccine strategy (Vac 1-Vac 4), we assessed
the incremental costs incurred and QALYs gained to cal-
culate the incremental cost-effectiveness ratio (ICER) of
each vaccination strategy in every geography. The Com-
mission on Macroeconomics and Health suggests that
an intervention is considered to be very cost-effective if
its ICER is less than the gross domestic product (GDP)
per capita [30]. For each geography, we identified the
strategies (Vac 1–Vac 4) that were cost-effective under
this definition. We also estimated the maximum price
that could be paid for vaccination for the most expensive
strategy (vaccinate everyone over 45 in an environmen-
tally suitable area) to be cost-effective. In addition, we
conducted a regional analysis by aggregating costs and
vaccine effects over five United Nations regions: East
Asia and the Pacific (EAP), South Asia (SA), sub-
Saharan Africa (SAF), Latin America and the Caribbean
(LAC) and the Middle East and North Africa (MENA).
We performed probabilistic sensitivity analyses to exam-
ine the robustness of the results. A societal perspective
was employed using a 3% discount rate for both costs
and health benefits. A sensitivity analysis with 50% pro-
tective efficacy and 5 years protection was performed.
Results
Our synthesis of evidence from 12 observational studies
indicates that diabetes is the risk factor for melioidosis
with the highest relative risk, followed by age over 45 years
and chronic renal disease (Table 1). In the regional ana-
lysis, vaccinating diabetics aged over 45 years living in en-
vironmentally suitable areas for melioidosis (Vac 2) would
be cost-effective in EAP, SAF and SOA (Fig. 2; see Add-
itional file 1: Table S4 and Figure S2 for detailed results).
However, those vaccination strategies would not be cost-
effective in LAC and MENA. In the country/territory-level
analysis, vaccinating diabetics aged over 45 years (Vac 2) is
a cost-effective strategy in 45 geographies. Of these, vac-
cinating individuals aged over 45 years with either diabetes
or chronic renal diseases (Vac 3) is the optimum strategy
in six geographies, while vaccinating everyone aged over
45 years with or without diabetes/chronic renal disease
(Vac 4) is optimal in ten geographies (Additional file 1:
Table S5). However, in 22 geographies, none of the strat-
egies tested (Vac 1-Vac 4) are cost-effective (Fig. 3). Fig-
ure 4 shows the cost-effectiveness of vaccinating the
diabetic population aged over 45 years (Vac 2) in each
geography, as a ratio of GDP per capita.
Of 5.47 billion people across the 83 evaluated geog-
raphies, 1.55 billion are predicted to live in environmen-
tally suitable areas for melioidosis transmission [3]. Of
these, 457 million are > 45 years old. If the optimal cost-
effective strategy in Additional file 1: Table S5 was ap-
plied in each of the 61 geographies where one of the
vaccine strategies was found to be cost-effective, 5.26
million people would be vaccinated per year, averting on
Table 1 Parameters used in the analysis (Continued)
Values References
Antibiotics (per day), adults aged > 15 years High Middle Low
Meropenem 62.37 79.30 N/A [32, 33]
Ceftazidime 43.39 5.35 5.35
Trimethoprim/sulfamethoxazole 1.12 0.06 0.06
Co-amoxiclav 1.06 2.11 2.11
Health-related quality of life (utility)
Bacteraemia 0.36 (0.33, 0.38) [28]
General population 0.84 [29]
Life expectancy WHO Life Table [23]
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average 69,000 lost QALYs, 8400 cases and 4500 deaths
(i.e. 5.09% reduction in total burden) per vaccinated age
cohort. Vaccination would cost USD62.1 million per year
but save USD2.47 million in treatment costs. The re-
gions in order of the magnitude of projected reductions
in cases are EAP, SOA, SAF, LAC and MENA (with re-
ductions in total burden of 6.72%, 5.30%, 3.87%, 3.58%
and 1.99% respectively).
Alternatively, if everyone aged 46 living in an envir-
onmentally suitability area was vaccinated (Vac 4), then
Fig. 2 Results of the base case analysis assuming 80% vaccine protective efficacy with 5-year mean protective duration. a Map showing number
of lives saved by geography per 100,000 diabetics aged > 45 years vaccinated in environmentally suitable regions (strategy Vac 2). b Bar plot
showing the total number of deaths averted by region for each vaccination strategy. c Bar plot showing the net costs of vaccination by region
for each vaccination strategy
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15.18 million people would be vaccinated per year. This
could potentially prevent 13,628 cases of melioidosis
and 7386 deaths (9.4% reduction) with a gain of 113,
407 QALYs per vaccinated age cohort. If the cost of
vaccination was not fixed, then under this scenario the
threshold cost of vaccination (averaged across all coun-
tries) would be USD18.54, giving a potential market
size of USD281.32 million per year (ignoring vaccine
distribution costs).
A sensitivity analysis showed that with only 50% vaccine
protection, vaccinating diabetics aged over 45 years (Vac 2)
is a cost-effective strategy in 43 geographies. In addition,
vaccinating individuals aged over 45 years with diabetes
and/or chronic renal disease (Vac 3) is the optimum strat-
egy in three geographies, while vaccinating everyone aged
over 45 years with or without diabetes/chronic renal disease
(Vac 4) is optimal in five geographies. In 32 geopraphies,
none of the strategies tested (Vac 1-Vac 4) are cost-effective
(Additional file 1: Figure S3(a-g) and Table S6). If the opti-
mal cost-effective strategy was applied in each of the 51
geographies, 3.55 million people would be vaccinated
per year, averting on average 35,370 lost QALYs, 4311
cases and 2332 deaths (2.61% reduction) per vaccinated
age cohort.
Fig. 3 Geography-specific optimal cost-effective vaccination strategy and cost-effectiveness results of base case analysis by region. a Optimal
cost-effective vaccination strategy by geography. b Incremental cost-effectiveness ratio for each vaccine strategy by region. Strategies are
vaccinating (i) people over 45 years with chronic renal disease (Vac 1), (ii) people aged over 45 years with diabetes (Vac 2), (iii) people aged over
45 years with diabetes and/or chronic renal disease (Vac 3) and (iv) people aged over 45 years (Vac 4)
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Discussion
A recent disease burden study suggested that there are
around 165,000 cases and 89,000 deaths due to melioid-
osis every year and that the disease is endemic in at least
some parts of 83 geographies. Our impact and cost-ef-
fectiveness modelling indicates that a melioidosis
vaccine targeted at high-risk populations living in en-
vironmentally suitable areas for melioidosis transmis-
sion could reduce the burden of this disease in these
populations and be cost-effective. To our knowledge,
this is the first study evaluating the impact and eco-
nomic consequences of melioidosis vaccination from a
global perspective. In addition, this is the first study
systematically quantifying the relative risk of melioid-
osis in different groups by pooling evidence from a
review of observational studies.
Only one cost-effectiveness study of melioidosis vac-
cination has been published; this was restricted to
north-eastern Thailand but also found vaccination to be
potentially cost-effective [7]. Our analysis extends this
by considering all geographies with endemic melioidosis,
a wide range of risk factors based on a synthesis of stud-
ies in the literature, and a range of vaccine strategies. By
targeting the vaccine to the population at greatest risk,
we can ensure that vaccination is cost-effective even
when its duration of protection is short (5 years).
In addition, with the trend of increasing prevalence of
chronic renal disease and diabetes in some of the en-
demic countries, the size of the high-risk population
could increase considerably in the near future, making
the vaccine more cost-effective [25, 26]. The long-term
prognosis for these chronic diseases is improving in
Fig. 4 Geography-specific incremental cost-effectiveness ratio (ICER) per GDP per capita and comparative effectiveness results of base case
analysis by region. a Incremental cost-effectiveness ratio (ICER) of vaccinating the population over 45 years with diabetes (strategy Vac 2), as a
proportion of each geography’s GDP per capita. b ICER by region of each strategy compared to the next best strategy (Vac 2 compared with no
vaccination, Vac 3 compared with Vac 2, and Vac 4 compared Vac 3)
Luangasanatip et al. BMC Medicine          (2019) 17:129 Page 8 of 11
many countries, again making the protection from a
melioidosis vaccine potentially more valuable in the fu-
ture. On the other hand, melioidosis patients may have
better survival prospects due to the better quality and
accessibility of treatment [34].
The potential target areas for vaccination were deter-
mined from a study that determined environmentally
suitable areas for melioidosis with very high spatial reso-
lution (5 × 5 km2). However, the environmentally suit-
able areas generally do not correspond to administrative
boundaries between or within countries, especially in
large geographies such as Australia, China and India. In
practice, it may be easier to target vaccination strategies
by administrative units such as provinces or states based
on average risks within those units. Improving surveil-
lance systems at both the local and global levels would
also strengthen the robustness of data informing such
decisions.
This study has several limitations. Firstly, we considered
three risk factors for melioidosis in our evaluation: age
over 45 years, diabetes and chronic renal disease. These
have been consistently identified as some of the most im-
portant risk factors for melioidosis in studies. However,
other attributes have also been identified as potential risk
factors, although they are less consistently reported and/
or have smaller reported relative risks. They include
male gender, chronic lung disease, thalassaemia, exces-
sive alcohol consumption and being an indigenous
Australian [2, 12]. Further data about melioidosis rela-
tive risks and prevalence of these risk factors at the
country level may help more precisely targeted vaccin-
ation strategies that could increase vaccine impact and
cost-effectiveness further.
Secondly, many parameters around treatment proto-
cols and costs were estimated for broad categories of
geographies stratified by income level. Furthermore,
some parameters had to be established through expert
elicitation due to limitations in available data. Eco-
nomic studies at the country/territory level could help
establish more reliable estimates of the economic bur-
den of melioidosis.
Moreover, in the absence of explicit cost-effectiveness
threshold in most of the evaluated countries, we adopted
one GDP per capita to be the threshold which has been
widely used in low- and middle-income settings [30].
However, recent modelling evidence suggests that GDP
per capita thresholds are much higher than the actual
heath opportunity costs in several countries [35, 36].
Hence, our findings may require careful interpretation
and ideally supplemented by country-level analyses using
local thresholds and deliberative processes.
Lastly, as no melioidosis vaccines have entered human
trials to date, we made broad assumptions about the poten-
tial cost, protective efficacy and duration of protection
afforded by a vaccine. Our assumptions have been fairly
conservative: we assumed short duration (5 years), imper-
fect efficacy (50–80%) and vaccine cost assumptions based
on one of the most commercially successful vaccines to
date (human papillomavirus vaccine). By doing so, our ana-
lysis establishes the minimal characteristics of a vaccine that
can be successful in commercial and public health terms
for vaccine developers to aim for. Even with 50% protective
efficacy assumption in sensitivity analysis, a cost-effective
vaccine strategy still exists in 51 out of 83 melioidosis en-
demic countries. If a melioidosis vaccine is brought to mar-
ket with longer duration, better efficacy or a lower price,
then it will be even more cost-effective than we report.
Conclusions
In conclusion, our findings establish cost-effective strat-
egies for use of melioidosis vaccines in the majority of
environmentally suitable areas for transmission. These
results support the case for investors and manufacturers
to bring a candidate vaccine to the market, as well as to
donors and local decision makers to use such a vaccine
at the population level when it becomes available. Our
results also help in determining the market size and suit-
able price points for a vaccine if it becomes available.
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